Beauty Device Brands Take Heed: Ulthera Fraud Suit Rooted In ‘FDA-Approved’ Versus ‘FDA-Cleared’
This article was originally published in The Rose Sheet
The terms “FDA-approved” and “FDA-cleared” are not interchangeable; rather they denote distinct premarket regulatory pathways for medical devices with differing levels of FDA endorsement. Merz’s Ulthera unit recently failed to dismiss a false-advertising class action challenging its “FDA-approved” claims on an ultrasound system used in clinical settings for line and wrinkle treatment.
You may also be interested in...
German pharmaceutical firm Merz is expanding its aesthetics business with the agreed acquisition of Ulthera, a company specializing in non-surgical skin lifting, for up to $600m. The deal would mark Merz’s largest purchase in its history. It also illustrates an increasing interest from pharma companies in aesthetics, following Valeant’s hostile $54bn bid for Botox developer Allergan – the latter has so far resisted its rival’s overtures.
Subject to the approval of a federal bankruptcy court presiding over High Ridge Brands’ Chapter 11 case, private equity firm Tengram will add a raft of personal cleansing and hair-care brands to its portfolio while bringing back former High Ridge CEO James Daniels to head up the collection’s rejuvenation.
The European Commission issued requests on 4 February for updated opinions from the Scientific Committee on Consumer Safety on octocrylene, homosalate and benzophenone-3, in light of concerns that led to their listing in 2019 as “higher priority” substances used in cosmetics with endocrine-disrupting potential.